Literature DB >> 25416382

α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.

Nicola J Sinden, Michael J Baker, David J Smith, Jan-Ulrich Kreft, Timothy R Dafforn, Robert A Stockley.   

Abstract

The excessive activities of the serine proteinases neutrophil elastase and proteinase 3 are associated with tissue damage in chronic obstructive pulmonary disease. Reduced concentrations and/or inhibitory efficiency of the main circulating serine proteinase inhibitor α-1-antitrypsin result from point mutations in its gene. In addition, α-2-macroglobulin competes with α-1-antitrypsin for proteinases, and the α-2-macroglobulin-sequestered enzyme can retain its catalytic activity. We have studied how serine proteinases partition between these inhibitors and the effects of α-1-antitrypsin mutations on this partitioning. Subsequently, we have developed a three-dimensional reaction-diffusion model to describe events occurring in the lung interstitium when serine proteinases diffuse from the neutrophil azurophil granule following degranulation and subsequently bind to either α-1-antitrypsin or α-2-macroglobulin. We found that the proteinases remained uninhibited on the order of 0.1 s after release and diffused on the order of 10 μm into the tissue before becoming sequestered. We have shown that proteinases sequestered to α-2-macroglobulin retain their proteolytic activity and that neutrophil elastase complexes with α-2-macroglobulin are able to degrade elastin. Although neutrophil elastase is implicated in the pathophysiology of emphysema, our results highlight a potentially important role for proteinase 3 because of its greater concentration in azurophil granules, its reduced association rate constant with all α-1-antitrypsin variants studied here, its greater diffusion distance, time spent uninhibited following degranulation, and its greater propensity to partition to α-2-macroglobulin where it retains proteolytic activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25416382      PMCID: PMC4338942          DOI: 10.1152/ajplung.00179.2014

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  59 in total

Review 1.  Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy.

Authors:  David A Lomas; Ravi Mahadeva
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes.

Authors:  M L Brantly; J T Wittes; C F Vogelmeier; R C Hubbard; G A Fells; R G Crystal
Journal:  Chest       Date:  1991-09       Impact factor: 9.410

3.  Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema.

Authors:  P R Elliott; D Bilton; D A Lomas
Journal:  Am J Respir Cell Mol Biol       Date:  1998-05       Impact factor: 6.914

4.  Synthesis of antithrombin III and alpha-1-antitrypsin by the perfused rat liver.

Authors:  A Koj; E Regoeczi; C J Toews; R Leveille; J Gauldie
Journal:  Biochim Biophys Acta       Date:  1978-04-03

5.  Kinetics of association of human proteinases with human alpha 2-macroglobulin.

Authors:  G D Virca; J Travis
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

6.  Activation of human leukocyte elastase by human alpha2-macroglobulin.

Authors:  D Y Twumasi; I E Liener; M Galdston; V Levytska
Journal:  Nature       Date:  1977-05-05       Impact factor: 49.962

7.  Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Eur Respir J       Date:  2012-08-30       Impact factor: 16.671

Review 8.  Smoking-related diseases: the importance of COPD.

Authors:  C Zaher; R Halbert; R Dubois; D George; D Nonikov
Journal:  Int J Tuberc Lung Dis       Date:  2004-12       Impact factor: 2.373

9.  Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry.

Authors:  Robert A Stockley; David G Parr; Eeva Piitulainen; Jan Stolk; Berend C Stoel; Asger Dirksen
Journal:  Respir Res       Date:  2010-10-05

10.  Specific activity of alpha1proteinase inhibitor and alpha2macroglobulin in human serum: application to insulin-dependent diabetes mellitus.

Authors:  C L Bristow; F Di Meo; R R Arnold
Journal:  Clin Immunol Immunopathol       Date:  1998-12
View more
  18 in total

1.  Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions.

Authors:  Ian Loke; Ole Østergaard; Niels H H Heegaard; Nicolle H Packer; Morten Thaysen-Andersen
Journal:  Mol Cell Proteomics       Date:  2017-06-19       Impact factor: 5.911

Review 2.  Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis.

Authors:  David N O'Dwyer; Shanna L Ashley; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-29       Impact factor: 5.464

3.  Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease.

Authors:  Katie M Stiles; Dolan Sondhi; Stephen M Kaminsky; Bishnu P De; Jonathan B Rosenberg; Ronald G Crystal
Journal:  Chronic Obstr Pulm Dis       Date:  2018-08-17

Review 4.  Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.

Authors:  Maria J Chiuchiolo; Ronald G Crystal
Journal:  Ann Am Thorac Soc       Date:  2016-08

5.  Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.

Authors:  Alessandro N Franciosi; Brian D Hobbs; Oliver J McElvaney; Kevin Molloy; Craig Hersh; Louise Clarke; Cedric Gunaratnam; Edwin K Silverman; Tomás P Carroll; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

Review 6.  Neutrophil Modulation in Alpha-1 Antitrypsin Deficiency.

Authors:  Elizabeth Sapey
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

Review 7.  Alpha-1 Antitrypsin Deficiency: Have We Got the Right Proteinase?

Authors:  Robert A Stockley
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

8.  Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.

Authors:  Franz von Nussbaum; Volkhart M-J Li; Swen Allerheiligen; Sonja Anlauf; Lars Bärfacker; Martin Bechem; Martina Delbeck; Mary F Fitzgerald; Michael Gerisch; Heike Gielen-Haertwig; Helmut Haning; Dagmar Karthaus; Dieter Lang; Klemens Lustig; Daniel Meibom; Joachim Mittendorf; Ulrich Rosentreter; Martina Schäfer; Stefan Schäfer; Jens Schamberger; Leila A Telan; Adrian Tersteegen
Journal:  ChemMedChem       Date:  2015-06-17       Impact factor: 3.466

9.  Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung.

Authors:  Paul T King; Roleen Sharma; Kim M O'Sullivan; Judy Callaghan; Lovisa Dousha; Belinda Thomas; Saleela Ruwanpura; Steven Lim; Michael W Farmer; Barton R Jennings; Michaela Finsterbusch; Gavin Brooks; Stavros Selemidis; Gary P Anderson; Stephen R Holdsworth; Philip G Bardin
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

10.  Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity.

Authors:  P Gardiner; C Wikell; S Clifton; J Shearer; A Benjamin; S A Peters
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.